Table 1.

Baseline characteristics and crude incidence rate of lymphomas among biologic-naïve, TNFi, rituximab, tocilizumab or abatacept-treated patients with RA

	Bionaïve	TNFi	Rituximab	Tocilizumab	Abatacept	Total
No. of patients	71 088	47 864*	9094	2029	1708*	124 997*
Follow-up time (pyrs)	322 167	242 260*	29 810	2827	3352*	584 236*
Female (%)	72.1	74.8	79.0	80.1	78.0	73.7
Age mean (mean range)	61.1 (57–62)	55.0 (50–57)	57.9 (58–58)	55.9 (55–57)	57.5 (56–58)	58.5 (50–62)
No. of lymphomas	288	230	6	6	3	533
Incidence per 100 000 pyrs (95% CI)	89 (79–100)	81 (70–94)	20 (7–44)	177 (57–413)	60 (7–216)	85 (77–92)

*Because of the type of the register these data are missing from RATIO and GISEA, 38 incident TNFi-exposed lymphoma cases (RATIO: 27, GISEA: 11) and one abatacept-exposed patient (GISEA) were for that reason excluded from the calculation of the incidence rate.

GISEA, Italian Group for the Study of Early Arthritis; pyrs, patient-years; RA, rheumatoid arthritis; RATIO, French Research Axed on Tolerance of bIOtherapies; TNFi, tumour necrosis factor inhibitor.